1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. [DOI:10.3322/caac.21660]

2. Vardanjani HM, Haghdoost A, Bagheri-Lankarani K, Hadipour M. Estimation and Projection of Prevalence of Colorectal Cancer in Iran, 2015-2020. Adv Biomed Res 2018;7:20. [DOI:10.4103/abr.abr_178_16]

3. National Cancer Registry Ireland | Essential information on cancer in Ireland [Internet]. Avaiable from: https://www.ncri.ie/ [cited 29 January 2020].

4. Maajani K, Khodadost M, Fattahi A, Shahrestanaki E, Pirouzi A, Khalili F, et al. Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2019;20:13-21. [DOI:10.31557/APJCP.2019.20.1.13]

5. Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 2005;104:2035-47. [DOI:10.1002/cncr.21462]

6. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113-30. [DOI:10.1111/j.1365-2559.2006.02549.x]

7. Molina-Cerrillo J, San Román M, Pozas J, Alonso-Gordoa T, Pozas M, Conde E, et al. BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers (Basel) 2020;12:1571. [DOI:10.3390/cancers12061571]

8. Baltruškevičienė E, Mickys U, Žvirblis T, Stulpinas R, Pipirienė Želvienė T, Aleknavičius E. Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. Acta Med Litu 2016;23:24-34. [DOI:10.6001/actamedica.v23i1.3267]

9. Bhalla A, Zulfiqar M, Bluth MH. Molecular Diagnostics in Colorectal Carcinoma: Advances and Applications for 2018. Clin Lab Med 2018;38:311-42 [DOI:10.1016/j.cll.2018.02.008]

10. Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World J Clin Cases 2018;6:869-81. [DOI:10.12998/wjcc.v6.i15.869]

11. Guo F, Gong H, Zhao H, Chen J, Zhang Y, Zhang L, et al. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep 2018;8:6076. [DOI:10.1038/s41598-018-24306-1]

12. Li ZN, Zhao L, Yu LF, Wei MJ. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep (Oxf) 2020;8:192-205. [DOI:10.1093/gastro/goaa022]

13. Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol 2021;32:959-67. [DOI:10.1016/j.annonc.2021.03.206]

14. Lièvre A, de la Fouchardière C, Samalin E, Benoist S, Phelip JM, André T, et al. BRAF V600E-mutant colorectal cancers: Where are we? Bull Cancer 2020;107:881-95. [In French] [DOI:10.1016/j.bulcan.2020.04.017]

15. Shahjehan F, Kamatham S, Chandrasekharan C, Kasi PM. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. Drugs Today (Barc) 2019;55:683-693. [DOI:10.1358/dot.2019.55.11.3035584]

16. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009; 101:465-72. [DOI:10.1038/sj.bjc.6605164]

17. Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol 2019;11:1758835919856494. [DOI:10.1177/1758835919856494]

18. Sanz-Garcia E, Argiles G, Elez E, Tabernero J. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann Oncol 2017;28:2648-57. [DOI:10.1093/annonc/mdx401]

19. Poopak B, Rastan H, Rabieipoor S, Safari N, Madani Esfahani T, Jahangirpoor MA, et al . Evaluating The Diagnostic Value Of Braf - V600e Mutation Detection In Iranian Patients With Hairy Cell Leukemia. Studies in Medical Sciences 2016; 26 :881-88.

20. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular biomarkers for the evaluation of colorectal cancer. Am J Clin Pathol 2017;147:221-260. [DOI:10.1093/ajcp/aqw209]

21. Bartley AN, Hamilton SR, Alsabeh R, Ambinder EP, Berman M, Collins E, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med 2014;138:166-70. [DOI:10.5858/arpa.2013-0231-CP]

22. Bartley AN, Hamilton SR, Alsabeh R, Ambinder EP, Berman M, Collins E, et al. Members of the Cancer Biomarker Reporting Workgroup, College of American Pathologists. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med 2014;138:166-70. [DOI:10.5858/arpa.2013-0231-CP]

23. Baskovich BW, Schneider F, Baras A, Birdsong GG, Fitzgibbons PL, Khoury JD, et al. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non-Small Cell Carcinoma of the Lung. USA: College of American Pathologists (CAP); 2021.

24. Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, et al. KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. Cells 2020;9:219. [DOI:10.3390/cells9010219]

25. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med 2019;381:1632-43. [DOI:10.1056/NEJMoa1908075]

26. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 2011;6:e22769. [DOI:10.1371/journal.pone.0022769]

27. Sheikhsofla F, Poopak B, Firuzyar S, Roudbari F, Ghadiany M. A Cross-Sectional Study for Evaluation of KRAS and BRAF Mutations by Reverse Dot Blot, PCR-RFLP, and Allele-Specific PCR Methods Among Patients with Colorectal Cancer. Avicenna J Med Biotechnol 2021;13:183-91. [DOI:10.18502/ajmb.v13i4.7203]

28. Yari A, Afzali A, Aalipour M, Nakheai M, Zahedi MJ. KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. Caspian J Intern Med 2020;11:355-69.

29. Zeinalian M, Emami MH, Pourreza MR, Tabatabaiefar MA, Hashemzadeh-Chaleshtori, M. Somatic BRAF V600E Mutation in Familial Colorectal Cancer Type X: A New Study in Central Iran. Jentashapir Journal of Cellular and Molecular Biology 2021;12: 183-91. [DOI:10.5812/jjcmb.115099]

30. Javadi F, Geramizadeh B, Mirzai M. BRAF gene mutation analysis in colorectal cancer in south of Iran. Iranian Journal of Colorectal Research 2014; 2: 22-27. [DOI:10.17795/acr-19917]